{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:26:08Z","timestamp":1772792768016,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":11688,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1983,9]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>A prospective study was performed to evaluate the outcome of treatment withdrawal in 30 patients with \u201cautoimmune\u201d chronic active hepatitis in remission for periods of 1.5 to 9 years on maintenance corticosteroid and azathioprine therapy. Reactivation of disease, with marked rises in serum aminotransferase level (mean 668 \u00b1 S.D. 458 IU per liter) and accompanied by severe symptoms, occurred in 25 (87%) patients within 52 weeks (median 9 weeks; range 5 to 52) and was associated with the histological features of piecemeal necrosis and lobular hepatitis in all 20 liver biopsies examined. Age, sex, duration of disease and remission, presence of cirrhosis, autoantibody status, or immunoglobulin levels did not differentiate patients who relapsed from those who remained in remission. The response to reinstitution of treatment with prednisolone was satisfactory in 25 patients and clinical and biochemical abnormalities resolved within 10 weeks (median 6; range 3 to 10), death occurred in one patient within 48 hr of readmission to hospital.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.1840030510","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T12:14:11Z","timestamp":1278332051000},"page":"685-689","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":151,"title":["Relapse Following Treatment Withdrawal in Patients with Autoimmune Chronic Active Hepatitis"],"prefix":"10.1097","volume":"3","author":[{"given":"John E.","family":"Hegarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayhan T.","family":"Nouri Aria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Portmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian L. W. F.","family":"Eddleston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1002\/hep.1840030510-BIB1|cit1","first-page":"485","article-title":"Lupoid hepatitis: a comparison of 22 cases with other types of liver disease","volume":"31","author":"Mackay","year":"1962","journal-title":"Q J Med"},{"key":"10.1002\/hep.1840030510-BIB2|cit2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"10.1002\/hep.1840030510-BIB3|cit3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical and histological remission of severe chronic active liver disease: a controlled study of treatment and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.1840030510-BIB4|cit4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030510-BIB5|cit5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease; dose titration, standard dose and combination with azathioprine compared","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"10.1002\/hep.1840030510-BIB6|cit6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in Hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1002\/hep.1840030510-BIB7|cit7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM198101013040102","article-title":"Corticosteroid-treated chronic active hepatitis in remission","volume":"304","author":"Czaja","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840030510-BIB8|cit8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJM197607012950107","article-title":"Withdrawal from glucocorticoid therapy","volume":"295","author":"Byyny","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840030510-BIB9|cit9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0016-5085(80)90866-5","article-title":"Clinical features and prognosis of several chronic active liver disease (CALD) after corticosteroid induced remission","volume":"78","author":"Czaja","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.1840030510-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJM197406202902503","article-title":"Assessment of activity in chronic active liver disease: serum bile acids compared with conventional tests and histology","volume":"290","author":"Korman","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840030510-BIB11|cit11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gut.19.1.40","article-title":"Assessment of the (14C) aminopyrine breath test in liver disease","volume":"19","author":"Galizzi","year":"1978","journal-title":"Gut"},{"key":"10.1002\/hep.1840030510-BIB12|cit12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(76)91472-0","article-title":"Antibody dependent cell mediated (K-cell) cytotoxicity against isolated he-patocytes in chronic active hepatitis","volume":"1","author":"Cochrane","year":"1976","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030510-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM198211183072102","article-title":"The effects of corticosteroids on suppressor cell activity in \u201cautoimmune\u201d and viral chronic active hepatitis","volume":"307","author":"Nouri-Aria","year":"1982","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.1840030510","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-198309000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T11:04:19Z","timestamp":1733051059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-198309000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1983]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.1840030510","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[1983,9]]}}}